Minocycline

CAT: 0804-HY-17412A-01Size: 1 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-17412A-01Size:1 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF) -1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect[1][2][3][4][5][6][7].

CAS Number

10118-90-8

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Antibiotic; Apoptosis; Bacterial; Calcium Channel; HIF/HIF Prolyl-Hydroxylase; MDM-2/p53; Potassium Channel

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/minocycline.html

Purity

98.59

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4N(C)C)N

Molecular Formula

C23H27N3O7

Molecular Weight

457.48

Precautions

H302, H312, H332

References & Citations

[1]Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7.|[2]Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30 (8) :1381-93. |[3]Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125 (2) :433-40.|[4]Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32 (2) :380-6.|[5]Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80.|[6]Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5 (2) :575-88.|[7]Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654 (3) :274-9.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

L-type calcium channel

Citation 01

Alternative Products

Catalog	Name
M062-5MG	Minocycline
B1791-50	Minocycline HCl
TRC-M344800-100MG	Minocycline Hydrochloride
RM-M140334-01	Minocycline-d6
sc-203339E	Minocycline, Hydrochloride

Minocycline

Alternative Products

Popular Products